---
title: Asthma and COPD
layout: diseases
author: Corbin Cox
last-updated: 2018-7-22
created: 2017-12-8
toc: true
common: false
---



# Pathophysiology

## COPD

COPD is characterized by chronic bronchitis, emphysema, and inflamed airways. Emphysema is the abnormal enlargment of airspaces due to the destruction of alveolar wall tissue. Bronchitis is characterized by the inflammation of the bronchioles leading to hypertrophy and fibrosis of the respiratory smooth muscle, accompanied by mucosal gland enlargement and ciliary abnormalities. In the case of COPD, inflammation refers to increased oxidative stress, increased levels of proteases with decreased levels of antiproteases, as well as inflammation due to irritants such as cigarette smoke.

## Asthma

IgE mediated mast cell activation leads to the release of histamine, tryptase, leukotrienes, and prostaglandins leading to bronchoconstriction and vasodilation. Over the following hours, T<sub>H2</sub> lymphocytes are activated, leading to the release of interleukins and GM-CSF, which results in mucosal hyper secretion, goblet cell proliferation, and eosinophilic infiltration of lung tissue. Excessive immune activation also leads to some fibrosis of the airway. Lastly, due to chronic activation, smooth muscle hypertrophy is exhibited.

# Diagnosis and Staging

## COPD

### S/Sx

* Chronic Cough
* Dyspnea
* Increased Sputum Production
* Increased RR
* Use of Accessory Muscles to Breath
* Barrel Chest
* Decreased Breath Sounds
* Prolonged Exertion

![Barrel Chest](../images/barrel_chest.jpg)

### Risk Factors

* Smoking
* Genetics
* Age
* Hx of Asthma or other Reactive Airway Diseases
* Respiratory Infections
* FHx

### Dx

Spirometric Assessment with FEV<sub>1</sub>/FVC &lt; 0.7

### Staging

#### Symptomatic Assessment

| Stage | Symptomatic Assessment     | Exacerbations                  |
| :---- | :------------------------- | :----------------------------- |
| A     | CAT &lt; 10 OR mMRC &le; 1 | &le;1                          |
| B     | CAT &ge; 10 OR mMRC &ge; 2 | &le;1                          |
| C     | CAT &lt; 10 OR mMRC &le; 1 | &ge;2 OR &ge;1 Hospitalization |
| D     | CAT &ge; 10 OR mMRC &ge; 2 | &ge;2 OR &ge;1 Hospitalization |

#### Spirometric Airway Limitation

| Stage  | Impairment  | FEV<sub>1</sub> / FVC | FEV<sub>1</sub>     |
| :----- | :---------- | :-------------------- | :------------------ |
| GOLD 1 | Mild        | &lt;0.7               | &ge;80% Predicted   |
| GOLD 2 | Moderate    | &lt;0.7               | [50%,80%) Predicted |
| GOLD 2 | Severe      | &lt;0.7               | [30%,50%) Predicted |
| GOLD 3 | Very Severe | &lt;0.7               | &lt;30% Predicted   |

#### mMRC Grading

| mMRC Grade | Severity of Breathlessness               |
| :--------- | :--------------------------------------- |
| 0          | SOB w/ Strenuous Exercise                |
| 1          | SOB w/ Moderate Exertion (e.g. walking uphill or walking quickly) |
| 2          | SOB w/ Normal Activity (e.g. cannot keep up with others or must stop at normal pace) |
| 3          | SOB w/ Mild Activity (Walking for &lt;100m) |
| 4          | Cannot leave the house, SOB w/ dessing/undressing |

## Asthma

### SSx

* Chest-tightness
* Dyspnea
* Non-productive cough
* Wheezing

### Dx

* Reversible airway obstruction w/ bronchodilators
* Elevated IgE and eosinophils

### Staging

|                                     | Intermittent                                               | Mild-Persistent                                            | Moderate-Persistent                                          | Severe-Persistent                                            |
| ----------------------------------- | ---------------------------------------------------------- | ---------------------------------------------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ |
| SSx Frequency                       | &le; 2d / week                                             | &gt; 2x / week                                             | Daily                                                        | Multiple times / day                                         |
| Nighttime Awakening                 | &le; 2x / month                                            | 3-4x / month                                               | &gt; 1x / week                                               | &ge; 7x / week                                               |
| SABA Use                            | &le; 2d / week                                             | &gt; 2x weekly & &lt; 1 QD                                 | Daily                                                        | Multiple times / day                                         |
| Interference w/ Normal Activity     | None                                                       | Minor                                                      | Some                                                         | Severe                                                       |
| Lung Function Tests                 | FEV<sub>1</sub> &gt; 80%<br />FEV<sub>1</sub> / FVC Normal | FEV<sub>1</sub> &gt; 80%<br />FEV<sub>1</sub> / FVC Normal | FEV<sub>1</sub> [60%, 80%)<br />FEV<sub>1</sub> / FVC Reduced 5% | FEV<sub>1</sub> &lt; 80%<br />FEV<sub>1</sub> / FVC Reduced 5% |
| Exacerbations Requiring PO Steroids | 0-1                                                        | &ge; 2                                                     | &ge; 2                                                       | &ge; 2                                                       |



# Treatment

## COPD

### Maintenance Therapy

| GOLD Group | 1st Line       | 2nd Line          |
| :--------- | :------------- | :---------------- |
| A          | Bronchodilator | Try Another Class |
| B          | LABA           | LABA + LAMA       |
| C          | LAMA           | LABA + LAMA       |
| D          | LABA + LAMA    | LABA + LAMA + ICS |

GOLD C can conider a LABA + ICS combination for second line therapy; however it is not as effective. GOLD D can consider Roflumilast if FEV<sub>1</sub> &lt; 50% predicted w/ chronic bronchitis, and macrolide Abxs can be considered for former smokers.

### COPD Exacerbations

#### Treatment

* Albuterol w/ or w/o Ipratropium
* Prednisone 40mg PO QD x5d
* Abx
  * Macrolides, Amoxicillin/Clavulantate, or Tetracyclines x5-7d
  * Indicated w/ Ventilator Use or w/ Purulent Sputum and either Increased Sputum Volume or Dyspnea
* Can provide supplemental O<sub>2</sub>
* Consider non-invasive ventilation before intubation
* **If exacerbation pt is intubated and crashing, disconnect vent circuit, as respiratory arrest due to breath-stacking is very common
* Monitor Lung function annually

#### Discharge Criteria

* SABA not needed more than q4h
* Pt can cross room if they could at baseline
* Pt can eat and sleep w/o frequent awakening
* Clinically stable for 12-24hr

### Prevention / Non-Pharm

* Provide O<sub>2</sub> to increase O<sub>2</sub>Sat to &gt; 90%
* Smoking cessation
* Vaccination
  * Flu
  * Pneumococcal
* Transplant

## Asthma

### Maintenance Therapy

* Therapy proceeds in a stepwise manner
  * Start low, titrate as necessary
  * Below is general therapy level necessary for control
* Intermittent: Step 1
* Mild: Step 2
* Moderate: Step 3-4
* Severe: Step 5-6
* Step down if controlled for 3mo but do not eliminate ICS

|                         | Step 1   | Step 2                                 | Step 3                                                       | Step 4                                                       | Step 5                                      | Step 6                                 |
| ----------------------- | -------- | -------------------------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------- | -------------------------------------- |
| Reliever                | PRN SABA | PRN SABA                               | PRN SABA                                                     | PRN SABA and Low-Dose ICS / Formoterol                       | PRN SABA and Low-Dose ICS / Formoterol      | PRN SABA and Low-Dose ICS / Formoterol |
| Preferred Control Agent | None     | Low ICS                                | Low ICS / LABA                                               | Med or High ICS / LABA                                       | Add Tiotropium, Anti-IgE, or Anti-IL5       | Add low-dose PO GC                     |
| Alt Control Agents      | Low ICS  | Leukotriene Modifier<br />Theophylline | Med / High ICS<br />Low ICS + LT Modifier<br />Add Theophylline | Add Tiotropium<br />High ICS + LT Modifier<br />Add Theophylline | Add low-dose PO GC<br />Consider Omalizumab | Consider Omalizumab                    |

### Status Asthmaticus

* PO or IV GCs
  * 2 mg/kg prednisone equivalents QD NTE 60 mg QD
* Intermittent SABA / SAMA in ED
* O<sub>2</sub> to &ge; 90%
* Fluid resuscitation if necessary
* Consider non-invasive ventilation before intubation
* **If exacerbation pt is intubated and crashing, disconnect vent circuit, as respiratory arrest due to breath-stacking is very common
* Second Line
  * Switch from intermittent to continuous SABA
    * Albuterol 0.5 mg/kg/hr NTE 20 mg/hr
    * Monitor HR & K
  * MgSO<sub>4</sub> 25-75 mg/kg IV x1 dose NTE 2 g/dose
* Third Line
  * Terbutaline 
    * Monitor BP, HR, K
  * Aminophylline / Theophylline
    * Monitor HR / Rhythm, and plasma conc
    * Minimal evidence
  * Ketamine
  * Heliox
  * Volatile Anesthetics

### Prevention / Non-Pharm

* Avoid NSAIDs
* Vaccinate
  * Flu
  * Pneumococcal if &ge; 19yo
* Regular exercise

# Common Inhalers

| Brand Name                  | Active Ingredient(s)          | Class(es)   |
| :-------------------------- | :---------------------------- | :---------- |
| ProAir, Ventolin, Proventil | Albuterol                     | SABA        |
| Xopenex                     | Levalbuterol                  | SABA        |
| Atrovent                    | Ipratropium                   | SAMA        |
| Combivent                   | Albuterol / Ipratropium       | SABA / SAMA |
| QVAR                        | Beclomethasone                | ICS         |
| Pulmicort                   | Budesonide                    | ICS         |
| Alvesco                     | Ciclesonide                   | ICS         |
| Aerospan                    | Flunisolide                   | ICS         |
| Flovent, ArmonAir           | Fluticasone Propionate        | ICS         |
| Arnuity                     | Fluticasone Furoate           | ICS         |
| Asmanex                     | Mometasone                    | ICS         |
| Brovana                     | Arformoterol                  | LABA        |
| Foradil                     | Formoterol                    | LABA        |
| Arcapta                     | Indacaterol                   | LABA        |
| Striverdi                   | Olodaterol                    | LABA        |
| Servent                     | Salmeterol                    | LABA        |
| Tudorza                     | Aclidinium                    | LAMA        |
| Spiriva                     | Tiotropium                    | LAMA        |
| Incruse                     | Umeclidinium                  | LAMA        |
| Advair, AirDuo              | Fluticasone / Salmeterol      | ICS / LABA  |
| Symbicort                   | Budesonide / Formoterol       | ICS / LABA  |
| Dulera                      | Mometasone / Formoterol       | ICS / LABA  |
| Breo                        | Fluticasone / Vilanterol      | ICS / LABA  |
| Stiolto                     | Olodaterol / Tiotropium       | LABA / LAMA |
| Anoro                       | Vilanterol / Umeclidinium     | LABA / LAMA |
| Utibron                     | Indacanterol / Glycopyrronium | LABA / LAMA |
| Bevespi                     | Formoterol / Glycopyrronium   | LABA / LAMA |

## SEs

* &beta;-Agonists
  * Skeletal muscle tremors
  * Palpitations
  * Tachycardia
  * Hypokalemia
  * Hyperglycemia
  * Boxed warning for increased risk of Asthma-Related death was removed in 2018 **ADD CITATION HERE**
* Anticholinergics
  * Dry mouth
  * Dizziness
  * Blurred vision
  * Urinary retention
  * URIs

# Guidlines

* [2017 GOLD Pocket Guidlines](http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf)
* [2017 GOLD Guidlines](http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/)

# References

* Barrel Chest Image Available at [https://ratedmedicine.wordpress.com/barrel-chest/](https://ratedmedicine.wordpress.com/barrel-chest/)
